FDA and EMA align AI rules

The U.S. Food and Drug Administration and the European Medicines Agency have moved toward a common rulebook for artificial intelligence in drug development. (ema.europa.eu) The agencies published 10 joint principles on January 14, 2026, covering AI use from early research and clinical trials to manufacturing and post-market safety monitoring. The framework applies to medicine developers as well as companies filing or holding marketing authorizations. (fda.gov) In plain terms, the regulators are talking about software that helps generate or analyze evidence used to decide whether a drug is safe, effective, and manufactured to standard. Their January 2026 paper says AI in this context spans nonclinical work, clinical development, manufacturing, and post-marketing phases. (ema.europa.eu) The 10 principles start with “human-centric by design” and a “risk-based approach,” then move through standards, context of use, multidisciplinary expertise, data governance, model development, performance assessment, lifecycle management, and clear information. FDA says those principles are tailored to the drug-development cycle rather than borrowed from general-purpose software policy. (fda.gov) That matters for tools such as laboratory information systems, digital twins, and predictive models because the agencies are signaling that AI will be judged inside regulated quality systems, not as a black box sitting beside them. The EMA-FDA paper says AI outputs need management across development, deployment, use, and maintenance so results stay accurate and reliable. (ema.europa.eu) The joint principles do not create a binding law on their own. EMA said they are meant to underpin future guidance in each jurisdiction and support work with standards bodies and other regulators. (ema.europa.eu) Europe has already been building that path. EMA said European guideline development is underway on top of its reflection paper, adopted in September 2024, which laid out how AI and machine learning could be used across the medicinal-product lifecycle under existing legal requirements. (ema.europa.eu) The U.S. side has been moving in parallel. FDA published draft guidance in January 2025 on using AI to support regulatory decision-making for drug and biological products, with recommendations for sponsors using AI to produce information tied to safety, effectiveness, or quality. (fda.gov) EMA has also tied the new principles to a broader 2023-2028 artificial-intelligence workplan with the Heads of Medicines Agencies, which focuses on guidance, tools, collaboration, training, and experimentation inside medicines regulation. That means the joint FDA-EMA document sits inside a longer push to make AI reviewable by inspectors, assessors, and sponsors on both sides of the Atlantic. (ema.europa.eu) For drug companies, the message is less about buying a specific AI product than about proving how a model is used, what data trained it, how its risks were tested, and who is accountable when it changes. The agencies opened with alignment, but the practical test will be whether future submissions can show AI that regulators can trace, validate, and monitor. (ema.europa.eu)